Butorphanol

Butorphanol

SCHEMBL3354253

O=C(O)C(O)C(O)C(=O)O.Oc1ccc2c(c1)[C@@]13CCCCC1(O)[C@@H](C2)N(CC1CCC1)CC3

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRK1OPRM1

The experimentally established mechanism targets of Butorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
OPRK1 known ✓ P41145 19/20 0.83
OPRM1 known ✓ P35372 15/20 0.83
OPRD1 P41143 16/20 0.83
KCNH2 Q12809 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butorphanol SCHEMBL30008734 1.00 OPRK1 (0.83) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL41926 1.00 OPRK1 (0.83) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL30136229 1.00 OPRK1 (0.83) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL2727817 1.00 OPRK1 (0.83) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL29359664 0.91 OPRK1 (1.00) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL20904174 0.91 OPRK1 (1.00) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL27701479 0.91 OPRK1 (1.00) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL10031253 0.91 OPRK1 (1.00) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL16311889 0.91 OPRK1 (1.00) OPRK1OPRD1OPRM1KCNH2
Butorphanol SCHEMBL28094979 0.91 OPRK1 (1.00) OPRK1OPRD1OPRM1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557088-B2 Methods and compositions for treating conditions NEOPRO LABS, LLC (US) 2009-07-07 US claimed
EP-2015765-A2 METHODS AMD COMPOSITIONS FOR TREATING CONDITIONS Neopro Labs, LLC (US) 2009-01-21 EP claimed
US-20070259818-A1 Methods and Compositions for Treating Conditions NEOPRO LABS, LLC 2007-11-08 US claimed
WO-2007112453-A2 METHODS AMD COMPOSITIONS FOR TREATING CONDITIONS NEOPRO LABS, LLC (US) 2007-10-04 WO claimed
CN-109071414-B Improved process for the preparation of butorphanol tartrate 海蔻有限公司 2021-11-05 CN disclosed
EP-3436425-B1 AN IMPROVED PROCESS FOR THE PREPARATION OF BUTORPHANOL TARTRATE HIKAL LTD (IN) 2021-01-06 EP disclosed
US-10544101-B2 Process for the preparation of butorphanol tartrate HIKAL LIMITED (IN) 2020-01-28 US disclosed
US-20190112273-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF BUTORPHANOL TARTRATE HIKAL LIMITED (IN) 2019-04-18 US disclosed
EP-3436425-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF BUTORPHANOL TARTRATE Hikal Limited (IN) 2019-02-06 EP disclosed
WO-2017168444-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF BUTORPHANOL TARTRATE HIKAL LIMITED (IN) 2017-10-05 WO disclosed
US-9226918-B2 Methods and compositions for treating or preventing narcotic withdrawal symptoms THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2016-01-05 US disclosed
US-20100144754-A1 Methods and Compositions for Treating or Preventing Narcotic Withdrawal Symptoms THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2010-06-10 US disclosed
WO-2010065930-A1 METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING NARCOTIC WITHDRAWAL SYMPTOMS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2010-06-10 WO disclosed
US-7557088-B2 Methods and compositions for treating conditions NEOPRO LABS, LLC (US) 2009-07-07 US disclosed
US-20090069237-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS NEOPRO LABS LLC 2009-03-12 US disclosed
WO-2009012472-A2 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS NEOPRO LABS, LLC (US) 2009-01-22 WO disclosed
EP-2015765-A2 METHODS AMD COMPOSITIONS FOR TREATING CONDITIONS Neopro Labs, LLC (US) 2009-01-21 EP disclosed
US-20070259818-A1 Methods and Compositions for Treating Conditions NEOPRO LABS, LLC 2007-11-08 US disclosed
WO-2007112453-A2 METHODS AMD COMPOSITIONS FOR TREATING CONDITIONS NEOPRO LABS, LLC (US) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544101-B2 Process for the preparation of butorphanol tartrate OPRD1, OPRK1, OPRL1 OPRK1 2/4885OPRM1 4/4885OPRD1 1/4885
US-20190112273-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF BUTORPHANOL TARTRATE OPRD1, OPRL1, OPRK1 OPRK1 3/4885OPRM1 6/4885OPRD1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.